ACADIA Pharmaceuticals Inc. (ACAD): What’s Next For This Biotech?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) 1,100% gain makes it one of the best performing stocks in the market. This rally began after its Parkinson’s disease drug Pimavanserin produced a positive outcome in its Phase III trial.

In particular, Pimavanserin had no negative impact on motor function and significantly reduced psychotic episodes compared to placebo. The drug’s likelihood for approval is now all but a guarantee, and investors are buying like crazy.

ACADIA Pharmaceuticals Inc. (ACAD)

Moreover, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) does not have to complete another late-stage study, as previously expected. This fact has created much of the gains following its initial 150% pop in November 2012. Therefore, it is expected that Pimavanserin will be approved by early next year and then available in the market in late 2014 or early 2015.

In terms of upside, Pimavanserin’s expected sales for the Parkinson’s disease Psychosis indication is between $300 and $400 million annually. The real upside for Pimavanserin lies in off-label uses and its expanded use. Most believe that it will be used in schizophrenia, bipolar disorder, and other diseases where antipsychotics are necessary. Thus, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is poised to benefit from a large $18 billion market, and many have projected that Pimavanserin’s label and off-label uses combined could generate sales north of $1 billion annually.

What To Do Next

As a long-term investment, I think ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the best places to put money to work in the market. As a short-term investment, its stream of catalysts are running low.

Acadia has seen its large run-up because of how cheap it was prior to Pimavanserin’s data. Now, with a $1.25 billion market cap, the only catalyst remaining is its meeting with the FDA and the eventual launch.

While these two events are important, 16 months of inactivity and a lack of headlines can hurt a biotechnology stock. Also, during the launch and approval process, sometimes warnings and negative information is found that was previously undiscovered.

Thus, stocks that run higher before these events, often trade lower as all good news is already priced into the stock. Therefore, if you own ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with gains of 300% plus, it might be wise to take some profits off the table – especially if you’re not planning to hold the stock for multiple years.

The Only Likely Catalyst

While the catalysts will be few and far between over the next 16 months, there is one possible catalyst remaining, and that is an acquisition.

Like I said, the antipsychotic market is massive, and one where most large pharma companies have drugs available. However, many of these antipsychotic drugs are being replaced with newer and better drugs, along with losing patent protection.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has full rights to Pimavanserin, and with it being an innovating drug with large potential sales, it seems logical that large pharma would show a considerable amount of interest. If in fact the company is for sale and the large pharma company has an antipsychotic segment.

One company in particular that has been discussed often is AstraZeneca plc (ADR) (NYSE:AZN), a very large $65 billion company. The reason it has been mentioned is because it owns Seroquel – but is facing generic threats. The acquisition of Acadia could reignite AstraZeneca plc (ADR) (NYSE:AZN)’s antipsychotic line of products, and seems to be a good match.

Then, there is Acadia’s partnership with Allergan, Inc. (NYSE:AGN). However, this partnership is for the development of Acadia’s early stage products, as Allergan, Inc. (NYSE:AGN) is a company focused on the development of therapeutics for glaucoma and chronic pain. Thus, Allergan, Inc. (NYSE:AGN) may not have the resources to effectively launch and market Pimavanserin.

If Acadia is acquired, there’s little doubt in my mind that it will be under $2 billion. Pimavanserin has too much upside and when combined with large pharma’s sales force and manufacturing process, the profit margin for Pimavanserin could be north of 30%. As a result, a $2 billion acquisition would return a profit fairly quickly.

Conclusion

With all things considered, Acadia has been a great stock – but does not have upcoming catalysts. In fact, the only notable catalyst might be an acquisition, and it’s never a good idea to buy a stock on the speculation of an acquisition alone.

Thankfully, as we look long-term ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has great upside potential. In my opinion, the best way to play Acadia over the next year is to hold a small position, and to take gains off the table if you already own.

Currently, I say there is a 50/50 chance of the company being acquired, although it’s hard to know when it might occur. Therefore, by keeping a small position you are still exposed if an acquisition is announced, and if not, you can buy back on any potential dip during the next 16 months.

The article What’s Next For This Biotech? originally appeared on Fool.com and is written by Sherrie Stone.

Sherrie Stone has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Sherrie is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!